RELATED STUDY
Cannabidiol and Intestinal Motility: a Systematic Review
Key Findings: Evidence is limited but in vitro and preclinical data show promise for the use of cannabidiol (CBD) in improving intestinal motility and related conditions.
Type of Study: Meta-analysis
Study Sample Size: 21
Study Result: Positive
Research Location(s): United States
Year of Pub: 2024
Cannabinoids Studied: Cannabidiol (CBD), O-x Synthetic Cannabinoids, WIN-x Synthetic Cannabinoids, Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG)
Phytocannabinoid Source: Not Applicable
DOSING DETAILS 
Study Dosing Objective: Effective Dose, Safety Profile,
Established Protocol: Effective dose with adverse effects
Route of Administration: In vitro, Oral (Ingestion)
Cannabinoid Ratio: (CBD : Pharma CBD) 0 : 0 
Dosage Form: cannabidiol or Epidiolex
Maximum Dose: 20 mg/kg body mass/d
Adverse Events: CBD is not associated with major safety risks: changes in somnolence, decreased appetite, diarrhea, hormone changes, decreased fertility, and hepatic impairment at higher dosing.
Citation: Story G, et al. Cannabidiol and Intestinal Motility: a Systematic Review. Curr Dev Nutr. 2023; 7:101972. doi: 10.1016/j.cdnut.2023.101972
Authors: Story G, Briere CE, McClements DJ, Sela DA
